Journey Medical Corporation (DERM)
NASDAQ: DERM · Real-Time Price · USD
7.62
+0.15 (2.01%)
Apr 28, 2025, 4:00 PM EDT - Market closed
Journey Medical Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 |
| Operating Revenue | 55.13 | 59.66 | 71 | 63.13 | 44.53 | Upgrade
|
| Other Revenue | 1 | 19.52 | 2.67 | - | - | Upgrade
|
| Revenue | 56.13 | 79.18 | 73.67 | 63.13 | 44.53 | Upgrade
|
| Revenue Growth (YoY) | -29.11% | 7.48% | 16.69% | 41.77% | 27.52% | Upgrade
|
| Cost of Revenue | 20.88 | 22.89 | 30.78 | 25.58 | 14.59 | Upgrade
|
| Gross Profit | 35.26 | 56.29 | 42.89 | 37.55 | 29.94 | Upgrade
|
| Selling, General & Admin | 40.2 | 43.91 | 59.47 | 39.83 | 22.09 | Upgrade
|
| Research & Development | 9.86 | 7.54 | 10.94 | 16.56 | - | Upgrade
|
| Other Operating Expenses | -4.55 | - | - | - | - | Upgrade
|
| Operating Expenses | 48.93 | 55.22 | 70.41 | 56.39 | 22.09 | Upgrade
|
| Operating Income | -13.68 | 1.07 | -27.52 | -18.84 | 7.85 | Upgrade
|
| Interest Expense | -2.7 | -1.7 | -2.02 | -7.03 | -0.7 | Upgrade
|
| Interest & Investment Income | 0.76 | 0.32 | 0.06 | 0 | - | Upgrade
|
| Currency Exchange Gain (Loss) | -0.12 | -0.18 | -0.09 | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | - | - | - | -0.45 | - | Upgrade
|
| EBT Excluding Unusual Items | -15.74 | -0.49 | -29.57 | -26.32 | 7.15 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -6.5 | - | Upgrade
|
| Asset Writedown | - | -3.14 | - | - | - | Upgrade
|
| Other Unusual Items | 1.13 | - | - | -9.54 | - | Upgrade
|
| Pretax Income | -14.61 | -3.63 | -29.57 | -42.36 | 7.15 | Upgrade
|
| Income Tax Expense | 0.06 | 0.22 | 0.06 | 1.63 | 1.87 | Upgrade
|
| Net Income | -14.67 | -3.85 | -29.63 | -43.99 | 5.28 | Upgrade
|
| Net Income to Common | -14.67 | -3.85 | -29.63 | -43.99 | 5.28 | Upgrade
|
| Net Income Growth | - | - | - | - | 45.74% | Upgrade
|
| Shares Outstanding (Basic) | 20 | 18 | 18 | 10 | 9 | Upgrade
|
| Shares Outstanding (Diluted) | 20 | 18 | 18 | 10 | 11 | Upgrade
|
| Shares Change (YoY) | 12.06% | 4.00% | 72.05% | -5.96% | 7.55% | Upgrade
|
| EPS (Basic) | -0.72 | -0.21 | -1.69 | -4.32 | 0.58 | Upgrade
|
| EPS (Diluted) | -0.72 | -0.21 | -1.69 | -4.32 | 0.49 | Upgrade
|
| EPS Growth | - | - | - | - | 36.11% | Upgrade
|
| Free Cash Flow | -9.13 | 5.24 | -13.53 | -2.18 | 5.13 | Upgrade
|
| Free Cash Flow Per Share | -0.45 | 0.29 | -0.77 | -0.21 | 0.47 | Upgrade
|
| Gross Margin | 62.80% | 71.09% | 58.23% | 59.48% | 67.23% | Upgrade
|
| Operating Margin | -24.37% | 1.35% | -37.35% | -29.84% | 17.63% | Upgrade
|
| Profit Margin | -26.14% | -4.87% | -40.22% | -69.68% | 11.86% | Upgrade
|
| Free Cash Flow Margin | -16.26% | 6.62% | -18.37% | -3.45% | 11.53% | Upgrade
|
| EBITDA | -10.25 | 4.84 | -23.24 | -16.37 | 9.28 | Upgrade
|
| EBITDA Margin | -18.27% | 6.11% | -31.55% | -25.92% | 20.83% | Upgrade
|
| D&A For EBITDA | 3.42 | 3.77 | 4.28 | 2.47 | 1.43 | Upgrade
|
| EBIT | -13.68 | 1.07 | -27.52 | -18.84 | 7.85 | Upgrade
|
| EBIT Margin | -24.37% | 1.35% | -37.35% | -29.84% | 17.63% | Upgrade
|
| Effective Tax Rate | - | - | - | - | 26.14% | Upgrade
|
| Revenue as Reported | 56.13 | 79.18 | 73.67 | 63.13 | - | Upgrade
|
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.